DEVELOPMENT OF A RADIOIMMUNOASSAY FOR THE DETERMINATION OF BUPRENORPHINE IN BIOLOGICAL SAMPLES

被引:14
作者
DEBRABANDERE, L
VANBOVEN, M
DAENENS, P
机构
关键词
BUPRENORPHINE DETECTION; DRUG ABUSE; BIOLOGICAL SAMPLE; RADIOIMMUNOASSAY;
D O I
10.1039/an9931800137
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The development of a specific and sensitive radioimmunoassay for the detection of buprenorphine in urine samples is described. With minor adjustments, the assay was also applied to the analysis for buprenorphine in plasma samples. The 2-diazobenzoic acid derivative of buprenorphine has been prepared as a hapten. The immunization of rabbits with the hapten-bovine serum albumin conjugate resulted in the production of antibodies, which cross-reacted with N-dealkylbuprenorphine up to about the 90% level. The antibodies showed very low cross-reactivities with the 3-O-glucuronides and with the structural analogue etorphine. The assay was mainly used to pre-screen for buprenorphine in urine samples of persons suspected of Temgesic misuse and to determine buprenorphine in plasma samples. A linear calibration graph for buprenorphine was obtained after logit-log regression [Y = 0.383 (s, 0.059) - 0.535 X (s, 0.025); r = 0.997 (s, 0.001)]. The spiking recovery study showed a linear regression of Y(observed) = 0.94 + 0.84 X (expected); r = 0.997. Intra- and inter-assay relative standard deviations were <4.35 and <6.36%, respectively. A comparison study of the high-performance liquid chromatographic determination (X) to the radioimmunoassay (Y) resulted in the following regression equation for the urine samples: Y = 1.44 + 1.64 X(n = 32; r = 0.910) and Y = 0.007 + 1.58 X (n = 10; r = 0.930) for plasma specimens. The minimum detectable dose of the immunoassay was calculated to be 10 pg ml-1 (Student's t-distribution, p = 0.01, degrees of freedom = 8).
引用
收藏
页码:137 / 143
页数:7
相关论文
共 32 条
  • [11] ERLANGER BF, 1957, J BIOL CHEM, V228, P713
  • [12] FINDLAY JWA, 1981, CLIN CHEM, V27, P1524
  • [13] HANBROCK JM, 1976, OPIATES ENDOGENOUS O, P295
  • [14] RADIOIMMUNOASSAY OF BUPRENORPHINE IN URINE - STUDIES IN PATIENTS AND IN A DRUG CLINIC
    HAND, CW
    RYAN, KE
    DUTT, SK
    MOORE, RA
    OCONNOR, J
    TALBOT, D
    MCQUAY, HJ
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 1989, 13 (02) : 100 - 104
  • [15] HARPER I, 1983, NEW ZEAL MED J, V96, P777
  • [16] BUPRENORPHINE - REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY
    HEEL, RC
    BROGDEN, RN
    SPEIGHT, TM
    AVERY, GS
    [J]. DRUGS, 1979, 17 (02) : 81 - 110
  • [17] COATED CHARCOAL IMMUNOASSAY OF INSULIN
    HERBERT, V
    LAU, KS
    GOTTLIEB, CW
    BLEICHER, SJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1965, 25 (10) : 1375 - +
  • [18] KLEEMANN A, 1987, PHARM WIRKSTOFFE ERG
  • [19] ANTIBODIES TO BSA CONJUGATES OF MORPHINE DERIVATIVES - STRICT DEPENDENCY OF IMMUNOLOGICAL SPECIFICITY ON HAPTEN STRUCTURE
    KOIDA, M
    TAKAHASH.M
    MURAOKA, S
    KANETO, H
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 1974, 24 (01) : 165 - 167
  • [20] MARTIN MJ, 1975, RADIOIMMUNOASSAY CLI, P269